

December 15th, 2025

Leuven, Belgium



international bowel
ULTRASOUND GROUP

Platforms for Research and Clinical Trials

Alex Menys

CEO Motilent | Assoc. Prof. UCL

ibus-group.org

Platforms: the future

We need to bring complex data together with expert interpretation to advance IBD. Introducing Entrolytics

Entrolytics
v1.39.0
[Beth Fisher]

FP001
07/09/2024, 10:47:57
STG1052310201
US Abdomen with contrast

IBDFingerprint Completed
1.0.0-QA_IBD_FINGERPRINT_REPORT.0
02
Alex Meny
11/10/2024, 14:20:00

Baseline

Symptoms

Histology

Biochemistry

Mucosal

Transmural

Radar Chart - Data

Label

Baseline 9/30

Symptoms

Other

Source Score	Fingerprint Score
450.0	7

Biochemistry

CRP

Source Score	Fingerprint Score
450.0	7


Publish Report

Save & Close Report

STRIDE 7?

Motilent & Entrolytics

Part 'Think Tank' | Part Technology Platform | Part Biomarker developer



Used in >230 projects internationally & by Alimentiv for IUS & MRE central reading

1. A good platform must have mission alignment


- Provider needs alignment and deep connection with user needs.
- Generic solutions for specific problems cause problems.
- IUS has many, often unique, challenges and opportunities that demand disciplined and focused solutions.

2. A good platform needs stable foundations


- **Front end-** Data needs to be easy to upload, look at and markup
 - **Back end** - Data (and the annotations that go with it) need to be safe, backed up and transferable (between sites, to sponsors, between teams)
-
- Validation, traceability, support and trust are **non-negotiable** at all project sizes (AI is helping to drive this)
 - Pricing sensitivity & a business model designed to endure - trials take time.

3. A good platform needs well designed interfaces for all stakeholders

What it looks like....





What it does....



3. Well designed interfaces for all stakeholders

Easy upload, powerful tooling, simple interface for reading (see Bridge by Motilent)




Rational, validated & well documented tech stack

API's **Documentation**
SDK's **Traceability**


4. A good platform needs extensibility & composability

How we continue to develop against evolving requirements & manage complexity

2018 - see the data



2022- Quantify the data



2025- simplify ingestion



5. We must encourage healthy ecosystem incentives & community


IBUS eLearning



New indications & users



Mixed
modality




Patient self-scanning

1.8

IUS projects
onboarded per
week

Conclusion

- A Platform is not just a product you buy. It's where your value is realised.
- IUS poses a unique set of challenges for multiple stakeholders many of which can be tackled with technology.
- **Mission alignment, community and collaboration is key**



Thank you for listening

alex.menys@motilent.io

www.motilent.io

Motilent | Changing the way we see the gut